ALSO NOTED: SuperGen gains $20M milestone; Cubist wins FDA OK; and much more...

> MGI Pharma's move to begin marketing Dacogen as a blood cell disease therapy triggered a $20 million milestone payment to SuperGen. Report

> Cubist Pharmaceuticals scored a big win with the FDA's approval late yesterday for expanding the use of Cubicin to include bloodstream infections. Cubist has made expanded approval a key strategy and expects to net millions of additional revenue as it begins a wider marketing program. Report

> Drug makers are drawing heavy fire from consumer advocates who say that private deals worth tens of millions of dollars are keeping generic drug manufacturers away from their markets. In one case involving Bristol-Myers and Sanofi-Aventis, 10 lawsuits have been filed that tackle a deal that delays a generic competitor to Plavix for years. And regulators may be starting to pay close attention to these generic drug pacts. Report

> NovaDel Pharma says that the FDA has accepted its submission on its NDA for NitroMist as a complete response. Report

> Biopure announced that an FDA advisory committee will meet in two months to discuss a clinical trial of its blood-loss therapy, Hemopure. Report

> Highland Clan announced a reverse takeover of Raptor Pharmaceutical and a $5 million financing. Release

> Agile Therapeutics has completed a $12 million equity financing. Release

> Chutes & Ladders: MultiCell Technologies has hired Stephen M. Chang, Ph.D., as its new CEO. Release

And Finally… Researchers have tracked down the missing viral link in chimps that triggered the AIDS pandemic. Report